South Korea-based CrystalGenomics has reeled in $2.6 million in funding from the Korea Seoul Life Science Fund (KSLSF) to advance its R&D programs in pain and infectious diseases, including an NSAID for patients with osteoarthritis, according to a company release. The company noted U.S. venture firm Oxford Bioscience Partners and Hanwha Venture Capital's roles as general partners in its backer KSLSF. The government of South Korea was a major contributor to Boston-based Oxford's sixth fund announced in early 2011. Release